Annual Accounts Receivable
$296.94 M
+$56.94 M+23.72%
December 31, 2024
Summary
- As of February 24, 2025, HALO annual accounts receivable is $296.94 million, with the most recent change of +$56.94 million (+23.72%) on December 31, 2024.
- During the last 3 years, HALO annual accounts receivable has risen by +$204.83 million (+222.36%).
- HALO annual accounts receivable is now at all-time high.
Performance
HALO Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Receivable
$296.94 M
+$17.29 M+6.18%
December 31, 2024
Summary
- As of February 24, 2025, HALO quarterly accounts receivable is $296.94 million, with the most recent change of +$17.29 million (+6.18%) on December 31, 2024.
- Over the past year, HALO quarterly accounts receivable has stayed the same.
- HALO quarterly accounts receivable is now at all-time high.
Performance
HALO Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
HALO Accounts Receivable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +23.7% | 0.0% |
| 3 y3 years | +222.4% | +35.0% |
| 5 y5 years | +392.9% | +35.0% |
HALO Accounts Receivable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +222.4% | at high | +222.4% |
| 5 y | 5-year | at high | +392.9% | at high | +867.5% |
| alltime | all time | at high | -100.0% | at high | -100.0% |
Halozyme Therapeutics Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | $296.94 M(+23.7%) | $296.94 M(+6.2%) |
| Sep 2024 | - | $279.65 M(+28.9%) |
| Jun 2024 | - | $217.03 M(+13.3%) |
| Mar 2024 | - | $191.52 M(-20.2%) |
| Dec 2023 | $240.00 M(+27.1%) | $240.00 M(+9.1%) |
| Sep 2023 | - | $219.92 M(-3.6%) |
| Jun 2023 | - | $228.09 M(+13.6%) |
| Mar 2023 | - | $200.80 M(+6.3%) |
| Dec 2022 | $188.88 M(+105.1%) | $188.88 M(+21.1%) |
| Sep 2022 | - | $155.92 M(-3.7%) |
| Jun 2022 | - | $161.94 M(+40.8%) |
| Mar 2022 | - | $115.00 M(+24.8%) |
| Dec 2021 | $92.11 M(-6.7%) | $92.11 M(-18.7%) |
| Sep 2021 | - | $113.30 M(-26.7%) |
| Jun 2021 | - | $154.52 M(+72.7%) |
| Mar 2021 | - | $89.50 M(-9.4%) |
| Dec 2020 | $98.73 M(+63.9%) | $98.73 M(+54.8%) |
| Sep 2020 | - | $63.79 M(+66.8%) |
| Jun 2020 | - | $38.25 M(+24.6%) |
| Mar 2020 | - | $30.69 M(-49.0%) |
| Dec 2019 | $60.24 M(+96.9%) | $60.24 M(+45.8%) |
| Sep 2019 | - | $41.33 M(+25.7%) |
| Jun 2019 | - | $32.89 M(+14.2%) |
| Mar 2019 | - | $28.80 M(-5.9%) |
| Dec 2018 | $30.60 M(+34.8%) | $30.60 M(+8.7%) |
| Sep 2018 | - | $28.16 M(-16.2%) |
| Jun 2018 | - | $33.58 M(+24.1%) |
| Mar 2018 | - | $27.07 M(+19.3%) |
| Dec 2017 | $22.69 M(+39.7%) | $22.69 M(+49.3%) |
| Sep 2017 | - | $15.20 M(+0.9%) |
| Jun 2017 | - | $15.05 M(+15.5%) |
| Mar 2017 | - | $13.03 M(-19.7%) |
| Dec 2016 | $16.24 M(-51.3%) | $16.24 M(-10.1%) |
| Sep 2016 | - | $18.07 M(-24.8%) |
| Jun 2016 | - | $24.04 M(-8.3%) |
| Mar 2016 | - | $26.22 M(-21.4%) |
| Dec 2015 | $33.38 M(+242.0%) | $33.38 M(+265.7%) |
| Sep 2015 | - | $9.13 M(-13.6%) |
| Jun 2015 | - | $10.56 M(+22.9%) |
| Mar 2015 | - | $8.60 M(-11.9%) |
| Dec 2014 | $9.76 M | $9.76 M(+6.7%) |
| Sep 2014 | - | $9.15 M(-32.2%) |
| Jun 2014 | - | $13.49 M(+15.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2014 | - | $11.68 M(+20.3%) |
| Dec 2013 | $9.71 M(-38.9%) | $9.71 M(-60.4%) |
| Sep 2013 | - | $24.52 M(+122.4%) |
| Jun 2013 | - | $11.03 M(+6.3%) |
| Mar 2013 | - | $10.38 M(-34.7%) |
| Dec 2012 | $15.88 M(+601.9%) | $15.88 M(+255.7%) |
| Sep 2012 | - | $4.46 M(-21.5%) |
| Jun 2012 | - | $5.69 M(+2.5%) |
| Mar 2012 | - | $5.55 M(+145.3%) |
| Dec 2011 | $2.26 M(-2.8%) | $2.26 M(-63.7%) |
| Sep 2011 | - | $6.24 M(+38.7%) |
| Jun 2011 | - | $4.50 M(+159.7%) |
| Mar 2011 | - | $1.73 M(-25.6%) |
| Dec 2010 | $2.33 M(-45.1%) | $2.33 M(-11.2%) |
| Sep 2010 | - | $2.62 M(+16.3%) |
| Jun 2010 | - | $2.25 M(+11.5%) |
| Mar 2010 | - | $2.02 M(-52.4%) |
| Dec 2009 | $4.24 M(-41.6%) | $4.24 M(+167.0%) |
| Sep 2009 | - | $1.59 M(+78.0%) |
| Jun 2009 | - | $893.10 K(+87.3%) |
| Mar 2009 | - | $476.80 K(-93.4%) |
| Dec 2008 | $7.26 M(+831.6%) | $7.26 M(+385.6%) |
| Sep 2008 | - | $1.50 M(+28.8%) |
| Jun 2008 | - | $1.16 M(+2.7%) |
| Mar 2008 | - | $1.13 M(+45.0%) |
| Dec 2007 | $779.80 K(+110.7%) | $779.80 K(+87.0%) |
| Sep 2007 | - | $416.90 K(+3.7%) |
| Jun 2007 | - | $401.90 K(-27.3%) |
| Mar 2007 | - | $552.80 K(+49.4%) |
| Dec 2006 | $370.10 K(-10.6%) | $370.10 K(-3.7%) |
| Sep 2006 | - | $384.20 K(-4.1%) |
| Jun 2006 | - | $400.70 K(+234.8%) |
| Mar 2006 | - | $119.70 K(-71.1%) |
| Dec 2005 | $413.80 K(>+9900.0%) | $413.80 K(+901.9%) |
| Sep 2005 | - | $41.30 K(-39.1%) |
| Jun 2005 | - | $67.80 K(+2160.0%) |
| Sep 2003 | - | $3000.00(-9.1%) |
| Jun 2003 | - | $3300.00(+94.1%) |
| Mar 2003 | - | $1700.00(>+9900.0%) |
| Sep 2002 | - | $0.00(-100.0%) |
| Jun 2002 | - | $200.00(-99.2%) |
| Mar 2002 | - | $24.40 K |
| Dec 2001 | $0.00 | - |
FAQ
- What is Halozyme Therapeutics annual accounts receivable?
- What is the all time high annual accounts receivable for Halozyme Therapeutics?
- What is Halozyme Therapeutics annual accounts receivable year-on-year change?
- What is Halozyme Therapeutics quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Halozyme Therapeutics?
- What is Halozyme Therapeutics quarterly accounts receivable year-on-year change?
What is Halozyme Therapeutics annual accounts receivable?
The current annual accounts receivable of HALO is $296.94 M
What is the all time high annual accounts receivable for Halozyme Therapeutics?
Halozyme Therapeutics all-time high annual accounts receivable is $296.94 M
What is Halozyme Therapeutics annual accounts receivable year-on-year change?
Over the past year, HALO annual accounts receivable has changed by +$56.94 M (+23.72%)
What is Halozyme Therapeutics quarterly accounts receivable?
The current quarterly accounts receivable of HALO is $296.94 M
What is the all time high quarterly accounts receivable for Halozyme Therapeutics?
Halozyme Therapeutics all-time high quarterly accounts receivable is $296.94 M
What is Halozyme Therapeutics quarterly accounts receivable year-on-year change?
Over the past year, HALO quarterly accounts receivable has changed by $0.00 (0.00%)